The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Di Maio, M., Gallo, C., Leighl, N. B., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., De Placido, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9334 · Cited by 497
Self-citationDesign Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials
Rubinstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P., & Smith, M. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.149 · Cited by 408
Cited by
Advances in ovarian cancer therapy
Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3501-8 · Cited by 624
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments
Marchetti, C., De Felice, F., Romito, A., Iacobelli, V., Sassu, C. M., Corrado, G., Ricci, C., Scambia, G., & Fagotti, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.08.011 · Cited by 139
Self-citationOvarian cancer relapse: From the latest scientific evidence to the best practice
Luvero, D., Plotti, F., Aloisia, A., Montera, R., Terranova, C., Nardone, C. D. C., Scaletta, G., Lopez, S., Miranda, A., Capriglione, S., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.014 · Cited by 68
Self-citationSensitization of cancer cells to paclitaxel-induced apoptosis by canagliflozin
Huang, H., Kung, F.-L., Huang, Y.-W., Hsu, C.-C., Guh, J.-H., & Hsu, L.-C. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116140 · Cited by 12
Metadata
- Authors
- Pignata, S., Lorusso, D., Scambia, G., Sambataro, D., Tamberi, S., Cinieri, S., Mosconi, A. M., Orditura, M., Brandes, A. A., Arcangeli, V., Panici, P. B., Pisano, C., Cecere, S. C., Di Napoli, M., Raspagliesi, F., Maltese, G., Salutari, V., Ricci, C., Daniele, G., Piccirillo, M. C., Di Maio, M., Gallo, C., & Perrone, F.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 16
- Issue
- 5
- Pages
- 561-568
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2150683293
- Cited by
- 164
- References
- 2
- FWCI
- 20.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(15)70115-4
- The paper
- Pignata, S., Lorusso, D., Scambia, G., Sambataro, D., Tamberi, S., Cinieri, S., Mosconi, A. M., Orditura, M., Brandes, A. A., Arcangeli, V., Panici, P. B., Pisano, C., Cecere, S. C., Di Napoli, M., Raspagliesi, F., Maltese, G., Salutari, V., Ricci, C., Daniele, G., . . . Perrone, F. (2015). Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(15)70115-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.